Rituximab biosimilar - Merck

Drug Profile

Rituximab biosimilar - Merck

Alternative Names: MK-8808

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Follicular lymphoma
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 28 Jul 2016 Phase I development is ongoing in Rheumatoid Arthritis in Ukraine (NCT013904410)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Follicular lymphoma(Combination therapy, First-line therapy, Late-stage disease) in Russia (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Combination therapy) in Belarus (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top